Atria Investments Boosts Stake in Becton, Dickinson and Company

Atria Investments Inc has increased its ownership in Becton, Dickinson and Company (NYSE: BDX) by 16.9% during the third quarter, as revealed in its recent 13F filing with the Securities and Exchange Commission (SEC). The investment firm now holds 27,529 shares of the medical technology company, valued at approximately $5,153,000 after acquiring an additional 3,975 shares during this period.

Several other institutional investors have also adjusted their positions in Becton, Dickinson, contributing to a trend of increased investment interest. Notably, Gilbert & Cook Inc. raised its stake by 2.0% in the second quarter, now owning 2,844 shares valued at $490,000. Similarly, Mendel Money Management increased its holdings by 2.6%, acquiring 2,254 shares worth $388,000. Focus Financial Network Inc. added 2.2% to its stake, now holding 2,692 shares valued at $504,000. CX Institutional also expanded its position by 3.6%, bringing its total to 1,731 shares valued at $324,000.

As of the latest reports, approximately 86.97% of Becton, Dickinson’s stock is held by hedge funds and institutional investors.

Stock Performance and Financial Highlights

On Friday, shares of Becton, Dickinson opened at $175.95. The company has a market capitalization of $50.10 billion and key financial ratios indicate a stable position: a debt-to-equity ratio of 0.67, a quick ratio of 0.64, and a current ratio of 1.05. Over the past year, the stock has fluctuated between a low of $127.59 and a high of $185.02. The stock’s 50-day and 200-day simple moving averages are $198.82 and $192.26, respectively.

In its most recent quarterly earnings report, released on February 9, 2024, Becton, Dickinson reported earnings per share (EPS) of $2.91, exceeding analysts’ expectations of $2.81. The company generated revenue of $5.25 billion, surpassing the consensus estimate of $5.15 billion. Compared to the same quarter the previous year, revenue increased by 1.6%.

For the fiscal year 2026, Becton, Dickinson has projected an EPS of $12.350-$12.650, while analysts forecast an average EPS of $14.43 for the current fiscal year.

Dividends and Stock Buyback Initiatives

Becton, Dickinson has recently declared a quarterly dividend of $1.05 per share, set to be paid on March 31, 2024. Shareholders on record as of March 10, 2024 will receive this payment, which translates to an annualized dividend of $4.20 and a yield of 2.4%. The company’s dividend payout ratio currently stands at 68.52%.

Furthermore, the board of directors has authorized a stock buyback plan, permitting the repurchase of up to $10.00 million in outstanding shares. Such buyback initiatives are often perceived as a sign that management believes the stock is undervalued.

Analysts’ Perspectives and Price Targets

Recent reports from several research firms have adjusted their price targets for Becton, Dickinson. Wells Fargo & Company lowered its target from $184.00 to $157.00, maintaining an “equal weight” rating. Likewise, JPMorgan Chase & Co. reduced its price objective from $190.00 to $175.00 and issued a “neutral” rating.

In contrast, Barclays has initiated coverage with an “overweight” rating and set a target price of $202.00. Royal Bank of Canada has established a price target of $172.00, while Piper Sandler reissued a “neutral” rating, revising its price objective down to $170.00 from $205.00. Overall, the stock has received five “Buy” ratings, ten “Hold” ratings, and one “Sell” rating, according to data from MarketBeat, which indicates an average rating of “Hold” with a consensus price target of $195.46.

Insider Trading Activity

In related news, Executive Vice President Michael David Garrison sold 1,610 shares of Becton, Dickinson stock in a transaction dated January 15, 2024, at an average price of $207.46, totaling approximately $334,010.60. Following this transaction, Garrison holds 12,095 shares valued at about $2,509,228.70, reflecting an 11.75% decrease in ownership. Over the past ninety days, insiders have sold a total of 2,463 shares valued at approximately $501,530, with insiders currently holding 0.40% of the stock.

As Becton, Dickinson continues to navigate the evolving landscape of medical technology, market sentiment remains a critical factor influencing its future performance. Investors and analysts alike will be watching closely as the company implements its strategic initiatives and responds to market dynamics.